MedPath

A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients

Phase 1
Recruiting
Conditions
Seneorineural Deafness
Sudden Sensorineural Hearing Loss
Interventions
Biological: Placebo
Registration Number
NCT06249919
Lead Sponsor
Neuracle Science Co., LTD.
Brief Summary

The goal of this 2 step-up, exploratory study is to test safey, tolerability and PK/PD profiles in healthy volunteers and safety, tolerability and efficacy in sudden sensorineural hearing loss patients as an early salvage therapy.

The main questions it aims to answer are:

1. whether is it safe and tolerable when healthy volunteers and sudden sensorineural hearing loss patients take multiple doses of NS101 against FAM19A5

2. whether is it effective in reversing hearing capability in sudden sensorineural hearing loss patients who fails to show sufficient recovery despite of oral standard steroid therapy.

Patients and heathly volunteers will be given NS101 15mg/kg or 30mg/kg systemically less than 3 months per protocol.

This is placebo controlled, double blinded study, which means there will be a group who receives placebo (i.e. fake drug) for study purpose.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
118
Inclusion Criteria
  • unilateral ideopathic SSNHL greater than 55dB at the average of 4 frequencies in PTA (contralateral hearing is less than 30dB)
  • those who started standard treatment within 5 days after symptom onset
  • those who were treated with oral steroids for 14 days, but incomplete recovery was confirmed as type III/IV according to Siegel's criteria at the end of the 14-day treatment
Exclusion Criteria
  • other otologic or systemic diseases
  • retrocochlear lesion

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group BPlaceboNS101 30mg/kg IV infusion Biweekly for 6weeks in Healthy Volunteers (active:placebo=6:3)
Group APlaceboNS101 15mg/kg IV infusion Biweekly for 6weeks in Healthy Volunteers (active:placebo=6:3)
Group ANS101NS101 15mg/kg IV infusion Biweekly for 6weeks in Healthy Volunteers (active:placebo=6:3)
Cohort BPlaceboPlacebo 15mg/kg IV infusion Biweekly for 12weeks in Sudden Sensorineural Hearing Loss patients
Cohort ANS101NS101 15mg/kg IV infusion Biweekly for 12weeks in Sudden Sensorineural Hearing Loss patients
Group BNS101NS101 30mg/kg IV infusion Biweekly for 6weeks in Healthy Volunteers (active:placebo=6:3)
Primary Outcome Measures
NameTimeMethod
Phase 1b part: Change from Baseline in Safety ProfilesBaseline, Day1, Day2, Day3, Day14, Day15, Day16, Day17, Day28, Day29, Day30, Day32, Day43

Adverse Event, Serious Adverse Event, ratio of Treatment related Serisous Adverse Event with causality \& severity will be descriptively measured and collected in the following time frames

Phase 2a part: Changes from Baseline in Safety ProfilesBaseline, Week1, Week2, Week4, Week6, Week8, Week10, Week12, Week16, Week20

Adverse Event, Serious Adverse Event, ratio of Treatment related Serisous Adverse Event with causality \& severity will be descriptively measured and collected in the following time frames

Secondary Outcome Measures
NameTimeMethod
Phase 1b part: Change from Baseline in PK/PD profiles & Immunological AssayBaseline, Day1, Day2, Day3, Day14, Day15, Day16, Day17, Day28, Day29, Day30, Day32, Day43

Concentrations, Areas Under the Curve versus time curve, Times and Volumes of Distribution of various status verus time curve

Phase 2a part : Change from Baseline in PK/PD profiles & immunological AssayBaseline, Week1, Week2, Week4, Week6, Week8, Week10, Week12, Week16, Week20

Concentrations, Areas Under the Curve versus time curve, Times and Volumes of Distribution of various status verus time curve

Trial Locations

Locations (15)

Yonsei University Severance Hospital

🇰🇷

Seoul, Korea, Republic of

SCH University Hospital Bucheon

🇰🇷

Bucheon, Korea, Republic of

Inje University Ilsan Paik Hospital

🇰🇷

Ilsan, Korea, Republic of

Chonam National University Hospital

🇰🇷

Gwangju, Korea, Republic of

Pusan National University Hospital

🇰🇷

Pusan, Korea, Republic of

Myongji Hospital

🇰🇷

Ilsan, Korea, Republic of

Seoul National University Bundang Hospital

🇰🇷

Seongnam, Korea, Republic of

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

Hallym Sacred Heart Hospital

🇰🇷

Pyeongchon, Korea, Republic of

Catholic University Seoul St. Mary's Hospital

🇰🇷

Seoul, Korea, Republic of

Korea University Anam Hospital

🇰🇷

Seoul, Korea, Republic of

Ajou University Hospital

🇰🇷

Suwon, Korea, Republic of

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

Wonju Severance Christian Hospital

🇰🇷

Wonju, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath